uniQure N.V. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- uniQure N.V. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00.
- uniQure N.V. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $300.23M.
- uniQure N.V. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $0.00.
- uniQure N.V. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $80.51M.
- uniQure N.V. stock issued during period, value, new issues for fiscal 2025 was $380.74M.
- uniQure N.V. stock issued during period, value, new issues for fiscal 2021 was $29.56M.
- uniQure N.V. stock issued during period, value, new issues for fiscal 2019 was $242.67M, a 75.39% increase from fiscal 2018.
- uniQure N.V. stock issued during period, value, new issues for fiscal 2018 was $138.36M, a 62.22% increase from fiscal 2017.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $380.74M 10-K · filed 2026-03-02 |
| 2025-09-30 | $300.23M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | |
| 2025-03-31 | $80.51M 10-Q · filed 2026-05-05 | |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $29.56M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | |
| 2021-06-30 | $1.86M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $27.70M 10-Q · filed 2022-05-02 | |
| 2019-12-31 | -$117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $242.67M 10-K · filed 2022-02-25 |
| 2019-09-30 | $242.79M 10-Q · filed 2020-10-27 | |
| 2018-12-31 | -$130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $138.36M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | |
| 2018-06-30 | $138.49M 10-Q · filed 2019-07-29 | |
| 2017-12-31 | $85.29M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $10.00K 10-K · filed 2018-03-14 | |
| 2015-12-31 | $82.52M 10-K · filed 2018-03-14 | |
| 2014-12-31 | $84.46M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |